Any patients recruited to BOSS should also be considered for ChOPIN.
The ChOPIN/IPOD study aims to assess both epigenetic and genetic changes which lead to pre-malignancy and ultimately to cancer. The study has two interrelated parts: 1) Chopin biomarkers, array and assessment of clonal changes early in cancer; 2) Chopin/IPOD genome wide study (inherited predisposition of oesophageal diseases) – IPOD. The biomarker study will be conducted in patients who have undergone cancer resection operations and are being followed up by the clinical teams who will have clinical and pathological records. The IPOD study will aim to collect blood samples from patients with Barrett’s oesophagus for DNA analysis. This study is suitable for all patients recruited to BOSS.
The aims are to identify genes that predispose to Barrett’s and, through this work, to identify oesophageal cancer predisposition genes.
Update: March 2011
The trial is recruiting well with 52 sites active to date and others in the process of site approval. A total of 70 sites are required so these is still opportunity for pthers to show interest. Recruitment is ahead of schedule and the target of 3000 is looking very achievable.